Skip to content

Menu

Perkins Coie LLP. logo
HomeAbout UsOur TeamContact
logonotch

1600 PTAB & Beyond

Significant Patent Decisions and Developments Affecting The Life Sciences Industry

35 USC 316

Subscribe to 35 USC 316

Impact of the PTAB’s Motion to Amend Pilot Program

By Bryan D. Beel on January 5, 2021
Posted in Amendments, PTAB Procedures, Statistics
MTA cover

As part of the post-grant proceedings created in 2012 by the America Invents Act, a Patent Owner can choose to file a motion to amend its patent when that patent is challenged. See 35 U.S.C. § 316(d) (“Amendment of the patent.”); 37 CFR § 42.121 (“Amendment of the patent.”). For example, a Patent Owner may…

About This Blog

Perkins Coie’s 1600 PTAB and Beyond blog reports from the intersection of the life sciences industry and key decisions and developments from the Patent Trial and Appeal Board (PTAB), district courts and appellate courts. We focus on IP analyses and insights within a practical and actionable context.

Stay Connected

RSS LinkedIn Facebook Twitter youtube

Topics

  • Amendments
  • ANDAs
  • Anticipation
  • Appeals
  • Claim Construction
  • District Court Proceedings
  • Enablement
  • Estoppel
  • Evidentiary Issues
  • Experts
  • Federal Circuit
  • Final Written Decisions
  • Induced Infringement
  • Informative
  • Institution Decisions
  • Interference
  • IPR
  • Joinder
  • Obviousness
  • Parallel Proceedings
  • Patent Eligibility
  • PGR
  • POP
  • Precedential
  • Prior Art
  • PTAB Procedures
  • PTAB Tech Center 1600 Round-Up Archive
  • Real Party-in-Interest
  • Section 101
  • Section 102
  • Section 112
  • Section 314
  • Section 315
  • Section 325
  • Statistics
  • Supreme Court
  • Uncategorized
  • USPTO
  • Venue

Archives

Recent Posts

  • PTAB Declares that Broad Institute, MIT, and Harvard Inventors Were First to Invent a CRISPR-Cas Gene Editing System to Alter Gene Expression in Eukaryotic Cells
  • Federal Circuit Confirms the Broad Reach of IPR Estoppel
  • Real Parties-In-Interest: Guidance On Who Is An RPI-And Who Is Not-In Post-Grant Proceedings
  • Senator Tillis Asks the PTO to Reconsider Fintiv Factor Two
  • How reliable are trial dates relied on by the PTAB in the Fintiv analysis?

Perkins Coie Blogs

  • Asset Management ADVocate
  • California Land Use & Development Law Report
  • Cannabis Legal Highlights
  • Consumer Finance Legal Report
  • Consumer Protection Review
  • Derivatives & Repo Report
  • Food Litigation News
  • Founder Tip of the Week
  • N.D.Pa.L.
  • Privacy Quick Tips
  • The Fintech Report
  • Trade Secret Tracker
  • Virtual Currency Report
  • White Collar Briefly

1600 PTAB & Beyond

Significant Patent Decisions and Developments Affecting The Life Sciences Industry

RSS LinkedIn Facebook Twitter youtube

Perkins Coie LLP

AUSTIN |
ANCHORAGE |
BEIJING |
BELLEVUE |
BOISE |
CHICAGO |
DALLAS |
DENVER |
LOS ANGELES
MADISON |
NEW YORK |
PALO ALTO |
PHOENIX
PORTLAND |
SAN DIEGO |
SAN FRANCISCO |
SEATTLE |
SHANGHAI |
TAIPEI |
WASHINGTON, D.C.

About This Blog

Perkins Coie’s 1600 PTAB and Beyond blog reports from the intersection of the life sciences industry and key decisions and developments from the Patent Trial and Appeal Board (PTAB), district courts and appellate courts. We focus on IP analyses and insights within a practical and actionable context.

Copyright © 2022, Perkins Coie LLP. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
Law blog design & platform by LexBlog LexBlog Logo